Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28627357 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3366295 | 1.00 | — | — | |
| SCHEMBL28283349 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Methyl Alcohol SCHEMBL28726677 | 0.94 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4092706 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19305255 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL5145873 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3359595 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL3343601 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12157423 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006073465-A2 | MODIFIED MICROSURFACES AND METHODS OF THEIR MANUFACTURE | PROTIVERIS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20050260423-A1 | Modified microsurfaces and methods of their manufacture | PROTIVERIS, INC. | 2005-11-24 | — | — | US | claimed |
| US-20140186263-A1 | MALEIMIDE-FUNCTIONALIZED GOLD NANOPARTICLES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-07-03 | — | — | US | disclosed |
| WO-2012162820-A1 | MALEIMIDE-FUNCTIONALIZED GOLD NANOPARTICLES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2012-12-06 | — | — | WO | disclosed |
| US-20080039816-A1 | Carbohydrate-Encapsulated Quantum Dots for Bilogical Imaging | The Government of the United States of America as represented by the Secretary, Department of (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2006073465-A2 | MODIFIED MICROSURFACES AND METHODS OF THEIR MANUFACTURE | PROTIVERIS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20050260423-A1 | Modified microsurfaces and methods of their manufacture | PROTIVERIS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005093422-A2 | CARBOHYDRATE-ENCAPSULATED QUANTUM DOTS FOR BIOLOGICAL IMAGING | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186263-A1 | MALEIMIDE-FUNCTIONALIZED GOLD NANOPARTICLES | TTN, MB, SIGLEC9 | MEN1 12/4885KMT2A 1267/4885TSHR 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.